Gain Therapeutics Statistics
Total Valuation
GANX has a market cap or net worth of $72.88 million. The enterprise value is $60.41 million.
| Market Cap | 72.88M |
| Enterprise Value | 60.41M |
Important Dates
The next estimated earnings date is Wednesday, November 11, 2026, before market open.
| Earnings Date | Nov 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
GANX has 43.64 million shares outstanding. The number of shares has increased by 39.34% in one year.
| Current Share Class | 43.64M |
| Shares Outstanding | 43.64M |
| Shares Change (YoY) | +39.34% |
| Shares Change (QoQ) | +1.54% |
| Owned by Insiders (%) | 2.31% |
| Owned by Institutions (%) | 20.42% |
| Float | 42.63M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 6.41 |
| P/TBV Ratio | 6.54 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.36, with a Debt / Equity ratio of 0.05.
| Current Ratio | 4.36 |
| Quick Ratio | 4.11 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -268.30% and return on invested capital (ROIC) is -148.18%.
| Return on Equity (ROE) | -268.30% |
| Return on Assets (ROA) | -95.51% |
| Return on Invested Capital (ROIC) | -148.18% |
| Return on Capital Employed (ROCE) | -160.97% |
| Weighted Average Cost of Capital (WACC) | 5.28% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$957,441 |
| Employee Count | 21 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, GANX has paid $906,540 in taxes.
| Income Tax | 906,540 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -24.77% in the last 52 weeks. The beta is 0.19, so GANX's price volatility has been lower than the market average.
| Beta (5Y) | 0.19 |
| 52-Week Price Change | -24.77% |
| 50-Day Moving Average | 1.83 |
| 200-Day Moving Average | 1.99 |
| Relative Strength Index (RSI) | 40.48 |
| Average Volume (20 Days) | 461,795 |
Short Selling Information
The latest short interest is 2.89 million, so 6.62% of the outstanding shares have been sold short.
| Short Interest | 2.89M |
| Short Previous Month | 2.80M |
| Short % of Shares Out | 6.62% |
| Short % of Float | 6.77% |
| Short Ratio (days to cover) | 8.28 |
Income Statement
| Revenue | n/a |
| Gross Profit | -9.99M |
| Operating Income | -19.30M |
| Pretax Income | -19.20M |
| Net Income | -20.11M |
| EBITDA | -19.25M |
| EBIT | -19.30M |
| Earnings Per Share (EPS) | -$0.51 |
Balance Sheet
The company has $13.08 million in cash and $609,874 in debt, with a net cash position of $12.47 million or $0.29 per share.
| Cash & Cash Equivalents | 13.08M |
| Total Debt | 609,874 |
| Net Cash | 12.47M |
| Net Cash Per Share | $0.29 |
| Equity (Book Value) | 11.29M |
| Book Value Per Share | 0.26 |
| Working Capital | 11.54M |
Cash Flow
| Operating Cash Flow | -18.95M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 49,531 |
| Net Borrowing | -100,843 |
| Free Cash Flow | -18.95M |
| FCF Per Share | -$0.43 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
GANX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -39.34% |
| Shareholder Yield | -39.34% |
| Earnings Yield | -27.42% |
| FCF Yield | -25.85% |
Analyst Forecast
The average price target for GANX is $7.20, which is 331.14% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $7.20 |
| Price Target Difference | 331.14% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |